About: Shaji K Kumar

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Shaji K Kumar Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	researcher (en) 연구원 (ko) investigador (es) araştırmacı (tr) wetenschapper (nl) дослідник (uk) эрдэмтэн (mn) изилдөөчү (ky)
rdfs:label	Shaji K Kumar (en) Shaji K Kumar (nl)
skos:prefLabel	Shaji K Kumar (en) Shaji K Kumar (nl)
name	Shaji K Kumar (en) Shaji K Kumar (nl)
instance of	wds:Q85960198-57ACCB59-ABEA-4CE7-81E9-CD5B27062E88
instance of	Homo sapiens
skos:altLabel	Shaji Kumar (en)
occupation	wds:Q85960198-125F90AE-8517-4631-8631-CE6FF21906F8
VIAF ID	wds:Q85960198-ac81506f-dabb-4aba-92db-1b9ac2d09a66
GND ID	wds:Q85960198-5113843e-06c6-4e7a-8472-73ba3155b0f8
Library of Congress authority ID	wds:Q85960198-D48D89BB-8B71-475D-BE58-328FFA55A11E
on focus list of Wikimedia project	wds:Q85960198-959189A7-EBCD-4BC0-8CB3-0A22B1C43194
National Library of Israel J9U ID	wds:Q85960198-B27FDA19-A1CE-4C28-B3E2-4AE0C50F73DE
VIAF ID	http://viaf.org/viaf/315240025
GND ID	https://d-nb.info/gnd/1170826083
Library of Congress authority ID	http://id.loc.gov/authorities/names/n2010181889
occupation	researcher
VIAF ID	315240025
GND ID	1170826083
Library of Congress authority ID	n2010181889
on focus list of Wikimedia project	WikiProject COVID-19
National Library of Israel J9U ID	987007352310205171
ORCID iD	wds:Q85960198-2E2A1244-FC52-4A05-868E-741D8F678209
ORCID iD	https://orcid.org/0000-0001-5392-9284
ORCID iD	0000-0001-5392-9284
ResearcherID	wds:Q85960198-6F3ADCCA-7370-433A-9E0F-EC059DFD588C
ResearcherID	A-9853-2008
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q85960198
is author of	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Improved survival in multiple myeloma and the impact of novel therapies Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. Clinical use and applications of histone deacetylase inhibitors in multiple myeloma Salvage second hematopoietic cell transplantation in myeloma Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Smoldering multiple myeloma requiring treatment: time for a new definition? Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report Immunophenotyping in multiple myeloma and related plasma cell disorders Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS. Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma Drug insight: thalidomide as a treatment for multiple myeloma Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software